News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CureLab, Inc., Canton Vaccine Firm, Plans North Dakota Move



12/17/2012 9:08:06 AM

Fargo biotechnology company Aldevron has been chosen to produce cancer vaccines being developed by a Boston-area research company that plans to move most of its operations to North Dakota. The DNA-based vaccines have shown promise in animal studies in suppressing lung and breast cancers, the Forum newspaper reported. CureLab Oncology will keep a lab and office in Canton, but plans to move most of its operations sometime next year to North Dakota, possibly to Fargo or Grand Forks, where it also is collaborating with Avianax, a biotech company at the University of North Dakota. The company will bring a few people to North Dakota but plans to hire local college and university graduates, CEO Alex Schneider said. ‘‘We already have put our foot on the soil,’’ Schneider said of the production partnership with Aldevron, which does custom DNA work for research labs around the world. The addition of CureLab to the area will help Fargo-Moorhead in its efforts to establish the area as a hub for the growing vaccine and biotech industries, said Michael Chambers, Aldevron’s chief executive.

Read at Boston Globe


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES